• T Klopfenstein, N J Kadiane-Oussou, L Toko, P-Y Royer, Q Lepiller, V Gendrin, and S Zayet.
• Infectious Diseases Department, Nord Franche-Comté Hospital, 90400 Trévenans, France. Electronic address: timothee.klopfenstein@hnfc.fr.
• Med Mal Infect. 2020 Aug 1; 50 (5): 436-439.

BackgroundMedical publications about anosmia with COVID-19 are scarce. We aimed to describe the prevalence and features of anosmia in COVID-19 patients.MethodsWe retrospectively included COVID-19 patients with anosmia between March 1st and March 17th, 2020. We used SARS-CoV-2 real time PCR in respiratory samples to confirm the cases.ResultsFifty-four of 114 patients (47%) with confirmed COVID-19 reported anosmia. Mean age of the 54 patients was 47 (±16) years; 67% were females and 37% were hospitalised. The median Charlson comorbidity index was 0.70 (±1.6 [0-7]). Forty-six patients (85%) had dysgeusia and 28% presented with pneumonia. Anosmia began 4.4 (±1.9 [1-8]) days after infection onset. The mean duration of anosmia was 8.9 (±6.3 [1-21]) days and 98% of patients recovered within 28 days.ConclusionsAnosmia was present in half of our European COVID-19 patients and was often associated with dysgeusia.Copyright © 2020 Elsevier Masson SAS. All rights reserved.

43 keywords...

hide…